{
    "Case ID": "013073",
    "Crime_Name": [
        "Patent Infringement Dispute"
    ],
    "Crime_Type": [
        "Property Crimes"
    ],
    "Dispute_Type": [
        "Patent Infringement and Invalidity Dispute"
    ],
    "Legal_Issue": [
        "Non-infringement of the 768 Patent",
        "Invalidity of the 546 Patent due to anticipation, obviousness, insufficient support, and double patenting"
    ],
    "Governing_Law": [
        "Section 6(1) of the Patented Medicines (Notice of Compliance) Regulations",
        "Subsection 27(3) of the Patent Act"
    ],
    "Procedural_Stage": [
        "Application under Section 6(1) of the NOC Regulations"
    ],
    "Evidence_Assessment": [
        "Claim construction analysis",
        "Expert testimonies",
        "Experimental data including solubility and averaging results",
        "Reliance on sodium salt data for calcium salt claims"
    ],
    "Decision_Outcome": [
        "768 Patent: Allegations of non-infringement unjustified; Ranbaxy prohibited from obtaining Notice of Compliance until patent expiry",
        "546 Patent: Allegations of invalidity justified; patent invalidated due to insufficient disclosure under s. 27(3)"
    ],
    "Burden_of_Proof": [
        "On applicant (Pfizer) to justify prohibition; on defendant (Ranbaxy) to prove invalidity or non-infringement"
    ],
    "Credibility_Factor": [
        "Assessment of expert testimony credibility and reliability of experimental data"
    ],
    "Legal_Rule": [
        "Full and correct disclosure required under s. 27(3) of the Patent Act",
        "Claim construction based on context and specification"
    ],
    "Standard_of_Review": [
        "Statutory review under NOC Regulations"
    ],
    "Procedural_Issue": [
        "Compliance with NOC procedural requirements for filing and responding to Notices of Allegation"
    ],
    "Grounds_for_Claim": [
        "Non-infringement (768 Patent)",
        "Invalidity by anticipation, obviousness, lack of utility, insufficient disclosure, double patenting (546 Patent)"
    ],
    "Outcome_on_Merits": [
        "In favor of Pfizer on 768 Patent",
        "In favor of Ranbaxy on 546 Patent"
    ],
    "Decision_Maker": [
        "Federal Court of Canada"
    ],
    "Judicial_Review_Outcome": [
        "Partial success for both parties"
    ],
    "Review_Standard": [
        "Statutory interpretation and application of patent law principles"
    ],
    "Procedural_Fairness_Assessment": [
        "Adherence to NOC Regulations process ensured fair hearing"
    ],
    "Key_Evidence_Considered": [
        "Patent claims and specifications",
        "Experimental data in patent disclosure",
        "Expert reports on solubility and bioavailability",
        "Data averaging practices"
    ],
    "Legal_Framework": [
        "Patent Act, NOC Regulations"
    ],
    "Applicant_Challenge": [
        "Pfizer challenged Ranbaxyâ€™s Notice of Allegation"
    ],
    "Court_Result": [
        "Prohibition granted regarding 768 Patent",
        "Application dismissed regarding 546 Patent"
    ],
    "Legal_Rule_Source": [
        "Patent Act, Canadian case law on claim construction and sufficiency"
    ],
    "Standard_of_Proof": [
        "Balance of probabilities"
    ],
    "Defendant_Response": [
        "Ranbaxy alleged non-infringement and invalidity of patents"
    ],
    "Evidence_Type": [
        "Documentary evidence (patents, regulatory submissions)",
        "Expert opinion evidence",
        "Experimental test data"
    ],
    "Remedy_Requested": [
        "Pfizer: Order prohibiting issuance of Notice of Compliance to Ranbaxy"
    ],
    "Outcome": [
        "768 Patent upheld, 546 Patent invalidated"
    ],
    "Decision_Authority": [
        "Federal Court"
    ],
    "Remedy_Sought": [
        "Prevention of generic market entry prior to patent expiry"
    ],
    "Resolution_Mechanism": [
        "Judicial determination under NOC Regulations"
    ],
    "Legal_Provision": [
        "Section 6(1), NOC Regulations",
        "Section 27(3), Patent Act"
    ],
    "Authority": [
        "Federal Court of Canada"
    ],
    "Claimant_Status": [
        "Pfizer as innovator brand company"
    ],
    "Legal_Provision_Cited": [
        "Section 6(1) of the NOC Regulations",
        "Subsection 27(3) of the Patent Act"
    ],
    "Grounds_for_Inadmissibility_or_Allegation": [
        "Insufficient disclosure",
        "Anticipation",
        "Obviousness",
        "Double patenting",
        "Non-infringement"
    ],
    "Applicable_Process": [
        "Notice of Compliance litigation process"
    ],
    "Outcome_of_Review": [
        "Mixed outcome: partial injunction granted"
    ],
    "Pending_Relief_or_Application": [
        "Application under Section 6(1) for prohibition"
    ],
    "Jurisdiction": [
        "Federal Court of Canada"
    ],
    "Governing_Rule": [
        "Patented Medicines (Notice of Compliance) Regulations, Patent Act"
    ]
}